Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal group A and C conjugate vaccine (Olin Biological)
- Development stage
- Unknown
- Lead developer
- Liaoning Chengda Biotechnology
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Meningococcal group A and C conjugate vaccine is a bivalent vaccine developed to prevent invasive meningococcal disease caused by *Neisseria meningitidis* serogroups A and C. The vaccine is composed of purified capsular polysaccharides from these two serogroups, each covalently conjugated to a carrier protein, such as tetanus toxoid. This conjugation process transforms the polysaccharides from T-cell independent to T-cell dependent antigens, which significantly enhances immunogenicity and induces immunological memory, particularly in infants and young children. Clinical evaluations, including Phase III and Phase IV studies conducted by Chengdu Olin Biotechnology, have demonstrated the vaccine's safety and its ability to elicit protective bactericidal antibody responses. It is primarily indicated for the prevention of epidemic cerebrospinal meningitis in healthy infants and children.
- Brand names
- Xifei
- Other names
- Group A and Group C Meningococcal Conjugate VaccineMenAC conjugate vaccineMeningococcal polysaccharide group A and C conjugate vaccine
02
Targets
NmA CPS (Neisseria meningitidis group A capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharide
Beyond the preview
Go deeper on meningococcal group A and C conjugate vaccine (Olin Biological).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal group A and C conjugate vaccine (Olin Biological).